Cabergoline treatment of risperidone-induced hyperprolactinemia: A pilot study

Roberto Cavallaro, Federica Cocchi, Sara M. Angelone, Enrico Lattuada, Enrico Smeraldi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: D2 blockers, including the atypical antipsychotic risperidone, induce hyperprolactinemia in a significant number of patients treated. The endocrine and sexual side effects related to hyperprolactinemia significantly impair tolerability and compliance in patients, including those with a good response to risperidone. This pilot study aimed to evaluate the efficacy and tolerability of a low dose of cabergoline, a D2 agonist, in the treatment of risperidone-induced hyperprolactinemia. Method: Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0.125 to 0.250 mg/week for 8 weeks. Plasma prolactin level was assessed at baseline and at the end of the study. Data were collected from January 2002 to April 2003. Results: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. No side effect was observed or reported, and the patients' psychopathology was unchanged. Conclusions: Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients.

Original languageEnglish
Pages (from-to)187-190
Number of pages4
JournalJournal of Clinical Psychiatry
Volume65
Issue number2
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Hyperprolactinemia
Risperidone
Prolactin
Therapeutics
Patient Compliance
Psychopathology
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Reference Values
cabergoline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Cabergoline treatment of risperidone-induced hyperprolactinemia : A pilot study. / Cavallaro, Roberto; Cocchi, Federica; Angelone, Sara M.; Lattuada, Enrico; Smeraldi, Enrico.

In: Journal of Clinical Psychiatry, Vol. 65, No. 2, 02.2004, p. 187-190.

Research output: Contribution to journalArticle

Cavallaro, Roberto ; Cocchi, Federica ; Angelone, Sara M. ; Lattuada, Enrico ; Smeraldi, Enrico. / Cabergoline treatment of risperidone-induced hyperprolactinemia : A pilot study. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 2. pp. 187-190.
@article{c716e4ab2fb44e5692e5b71f0fb9a909,
title = "Cabergoline treatment of risperidone-induced hyperprolactinemia: A pilot study",
abstract = "Background: D2 blockers, including the atypical antipsychotic risperidone, induce hyperprolactinemia in a significant number of patients treated. The endocrine and sexual side effects related to hyperprolactinemia significantly impair tolerability and compliance in patients, including those with a good response to risperidone. This pilot study aimed to evaluate the efficacy and tolerability of a low dose of cabergoline, a D2 agonist, in the treatment of risperidone-induced hyperprolactinemia. Method: Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0.125 to 0.250 mg/week for 8 weeks. Plasma prolactin level was assessed at baseline and at the end of the study. Data were collected from January 2002 to April 2003. Results: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. No side effect was observed or reported, and the patients' psychopathology was unchanged. Conclusions: Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients.",
author = "Roberto Cavallaro and Federica Cocchi and Angelone, {Sara M.} and Enrico Lattuada and Enrico Smeraldi",
year = "2004",
month = "2",
doi = "10.4088/JCP.v65n0207",
language = "English",
volume = "65",
pages = "187--190",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cabergoline treatment of risperidone-induced hyperprolactinemia

T2 - A pilot study

AU - Cavallaro, Roberto

AU - Cocchi, Federica

AU - Angelone, Sara M.

AU - Lattuada, Enrico

AU - Smeraldi, Enrico

PY - 2004/2

Y1 - 2004/2

N2 - Background: D2 blockers, including the atypical antipsychotic risperidone, induce hyperprolactinemia in a significant number of patients treated. The endocrine and sexual side effects related to hyperprolactinemia significantly impair tolerability and compliance in patients, including those with a good response to risperidone. This pilot study aimed to evaluate the efficacy and tolerability of a low dose of cabergoline, a D2 agonist, in the treatment of risperidone-induced hyperprolactinemia. Method: Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0.125 to 0.250 mg/week for 8 weeks. Plasma prolactin level was assessed at baseline and at the end of the study. Data were collected from January 2002 to April 2003. Results: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. No side effect was observed or reported, and the patients' psychopathology was unchanged. Conclusions: Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients.

AB - Background: D2 blockers, including the atypical antipsychotic risperidone, induce hyperprolactinemia in a significant number of patients treated. The endocrine and sexual side effects related to hyperprolactinemia significantly impair tolerability and compliance in patients, including those with a good response to risperidone. This pilot study aimed to evaluate the efficacy and tolerability of a low dose of cabergoline, a D2 agonist, in the treatment of risperidone-induced hyperprolactinemia. Method: Nineteen male and female DSM-IV-defined schizophrenic patients who were clinical responders to risperidone but were suffering from symptomatic hyperprolactinemia were treated with cabergoline, 0.125 to 0.250 mg/week for 8 weeks. Plasma prolactin level was assessed at baseline and at the end of the study. Data were collected from January 2002 to April 2003. Results: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. No side effect was observed or reported, and the patients' psychopathology was unchanged. Conclusions: Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients.

UR - http://www.scopus.com/inward/record.url?scp=1842844963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842844963&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n0207

DO - 10.4088/JCP.v65n0207

M3 - Article

C2 - 15003071

AN - SCOPUS:1842844963

VL - 65

SP - 187

EP - 190

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -